Mycosis Fungoides and the Sézary Syndrome Treatment–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (01/29/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage I Mycosis Fungoides

Editorial changes were made to this section.

Stage II Mycosis Fungoides

Editorial changes were made to this section.

Stage III Mycosis Fungoides

Editorial changes were made to this section.

Stage IV Mycosis Fungoides and the Sézary Syndrome

Editorial changes were made to this section.

Recurrent Mycosis Fungoides and the Sézary Syndrome

Added text to the list of treatment options under clinical evaluation to include interferon alpha alone or in combination with other agents, such as topical therapy (cited Foss et al. as reference 11 and Olsen et al. as reference 12). Also added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared time to next treatment (TTNT) between interferon alpha and conventional chemotherapy. Interferon alpha provided a longer TTNT of 8.7 months than did chemotherapy, with a TTNT of 3.9 months and P < .00001. Also added systemic chemotherapy: chlorambucil plus prednisone, mechlorethamine, cyclophosphamide, methotrexate, and combination chemotherapy to the list of treatment options under clinical evaluation (cited Kaye et al as reference 28, Rosen et al. as reference 29, and Zackheim et al. as reference 30). Chemotherapeutic agents generally demonstrate short durations of response. In a retrospective review of 198 patients with advanced-stage disease, the median time before patients required new therapy was 4 months.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Recurrent Mycosis Fungoides and the Sézary Syndrome

Next section >
About This PDQ Summary